partnering

News

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

Australia's CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other re

News

Lilly has committed $42.5 million over 10 years to fund pharmaceutical manufacturing scholarships for incoming Purdue undergraduate students, offering 75-100 talented students each year full tuition with a guaranteed internship (Purdue University photo)

Lilly deepens bonds with Purdue University with new funding ...

Eli Lilly's links to Purdue University go back a long way, and have been reinvigorated with $92.5 million in additional funding and renewed research collaborations.

News

AbbVie sheds autoimmune disease drug in blow to partner Inve...

Shares in French biotech Inventiva were on the slide this morning after AbbVie revealed that it had decided to abandon development of cedirogant, their drug candidate for autoimmune disease

News

Astellas makes another gene therapy play, takes stake in Tay...

Astellas has been having some safety-related issues with its gene therapy programmes of late, but it shows no signs of lessened enthusiasm for the category – as a new alliance with US biote

News

Gilead pledges $1.76bn to MacroGenics for bispecific cancer ...

Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, includ

News

GSK turns to AI specialist Tempus for R&D productivity boost

One of the first actions by GSK's recently appointed chief scientific officer, Tony Wood, has been to expand a partnership with Tempus aimed at improving the big pharma's R&D productivi

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

Lilly deepens bonds with Purdue University with new funding ...

AbbVie sheds autoimmune disease drug in blow to partner Inve...

Astellas makes another gene therapy play, takes stake in Tay...

Gilead pledges $1.76bn to MacroGenics for bispecific cancer ...

GSK turns to AI specialist Tempus for R&D productivity boost

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

partnering

Editor's Picks